阿昔单抗诱发血小板减少症及其治疗  

Abciximab-induced thrombocytopenia and its treatment

作　　者：严铭玉[1] 王骏[1] 王鸣和[1] 

机构地区：[1]上海市静安区中心医院心内科,上海200040

出　　处：《世界临床药物》2009年第2期118-120,共3页World Clinical Drug

摘　　要：急性冠状动脉综合征(ACS)或行经皮冠状动脉介入(PCI)的患者采用血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂治疗对改善临床预后起着关键作用。但该类药物所致血小板减少症已成为严重的并发症之一。本文就阿昔单抗诱发血小板减少症的诊断标准、鉴别诊断、监测指标、治疗及预后等进行简要阐述。In patients with acute coronary syndrome(ACS)or undergoing percutaneous coronary intervention(PCI),pharmacological blockade of the platelet glycoprotein Ⅱ b/Ⅲ a receptor inhibitor has emerged as a key strategy for improving clinical outcome.However,drug-induced thrombocytopenia is one of the severe complications.We discuss abciximab-induced thrombocytopenia,looking at its diagnostic criteria,differential diagnosis,monitoring markers,management and prognostic implications.

关 键 词：血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂 阿昔单抗 血小板减少症 

分 类 号：R541.4[医药卫生—心血管疾病]